|
1
|
Tanoue LT, Tanner NT, Gould MK and
Silvestri GA: Lung cancer screening. Am J Respir Crit Care Med.
191:19–33. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
World Cancer Report 2014. Stewart B and
Wild CP: IARC Nonserial Publication;
|
|
3
|
Szasz A: Current status of oncothermia
therapy for lung cancer. Korean J Thorac Cardiovasc Surg. 47:77–93.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ichite N, Chougule M, Patel AR, Jackson T,
Safe S and Singh M: Inhalation delivery of a novel diindolylmethane
derivative for the treatment of lung cancer. Mol Cancer Ther.
9:3003–3014. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
De Ruysscher D, Van Meerbeeck J, Vande
casteele K, Oberije C, Pijls M, Dingemans AM, Reymen B, van
Baardwijk A, Wanders R, Lammering G, et al: Radiation-induced
oesophagitis in lung cancer patients. Is susceptibility for
neutropenia a risk factor? Strahlenther Onkol. 188:564–567. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with non-
small-cell lung cancer harbouring mutations of the epidermal growth
factor receptor (WJ-TOG3405): An open-label, randomised phase 3
trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu Y, Du Y, Liu H, Ma T, Shen Y and Pan
Y: Study of efficacy and safety of pulsatile administration of
high-dose gefitinib or erlotinib for advanced non-small cell lung
cancer patients with secondary drug resistance: A single center,
single arm, phase II clinical trial. Thorac Cancer. 7:663–669.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yao C, Jiang J, Tu Y, Ye S, Du H and Zhang
Y: β-elemene reverses the drug resistance of A549/DDP lung cancer
cells by activating intracellular redox system, decreasing
mitochondrial membrane potential and P-glycoprotein expression, and
inducing apoptosis. Thorac Cancer. 5:304–312. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yao CC, Tu YR, Jiang J, Ye SF, Du HX and
Zhang Y: β-elemene reverses the drug resistance of lung cancer
A549/DDP cells via the mitochondrial apoptosis pathway. Oncol Rep.
31:2131–2138. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu Y, Ying W, Jia-li Y, Yan-Ting S and
Chun-ying L: Effects of Buzhong Yiqi decoction-medicated serum on
drug resistance of human lung adenocarcinoma cell line A549/DDP to
cisplatin. Chinese J Pathophysiol. 30:223–238. 2014.
|
|
12
|
Zhu CQ, da Cunha Santos G, Ding K,
Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire
JA, et al: Role of KRAS and EGFR as biomarkers of response to
erlotinib in National Cancer Institute of Canada Clinical Trials
Group Study BR.21. J Clin Oncol. 26:4268–4275. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brevet M, Johnson ML, Azzoli CG and
Ladanyi M: Detection of EGFR mutations in plasma DNA from lung
cancer patients by mass spectrometry genotyping is predictive of
tumor EGFR status and response to EGFR inhibitors. Lung cancer.
73:96–102. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ercan D, Choi HG, Yun CH, Capelletti M,
Xie T, Eck MJ, Gray NS and Jänne PA: EGFR mutations and resistance
to Irreversible pyrimidine-based EGFR inhibitors. Clin Cancer Res.
21:3913–3923. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang X and HU X: Research progress on the
anti-tumor mechanism and reversal mechanism of drug resistance of
β-elemene. J Mod Oncol. 22:1711–1714. 2014.
|
|
16
|
Jianfeng JU, Weiping YU, Chunsheng FU and
Liming MA: Modern research and clinical application of β-elemene.
Qilu Pharmaceutical Affairs. 27:546–548. 2008.
|
|
17
|
Guangchao LI: Basic research and clinical
applications of β-elemene. J Changchun Univ Tradit Chin Med.
25:185–186. 2009.
|
|
18
|
Lihua W and Fang S: Elemene emulsion
combined with NP chemotherapy in the treatment of advanced NSCLC
patients. China Oncol. 20:547–550. 2010.
|
|
19
|
Li T, Yuean C, Chaosheng P, Wei W and
Nanzhan L: Elemene emulsion combined with chemotherapy in the
treatment of patients with advanced non-small cell lung cancer.
Chinese J Clin Med. 16:725–727. 2009.
|
|
20
|
Qirong P, Bi X, Long M, Tao C, Yongcai T,
Caixia H and Pengfei L: Short-term clinical observation of Elemene
injection used to treat metaphase and advanced primary liver
cancer. Chin J Integ Tradit West Med Liv Dis. 20:274–276. 2010.
|
|
21
|
Dan Y, Guangyu A and Hong D: Efficacy
observation of advanced gastric cancer treated with elemene and
Tegafur. World J Integ Tradit West Med. 8:264–266. 2013.
|
|
22
|
Gao FY, Zhang AQ and Sun Y: Reversing
Effect of β-elemene on human lung adenocarcinoma cell line PC9.
Chin Arch Tradit Chin Med. 32:131–133. 2014.
|
|
23
|
Zhao S, Wu J, Zheng F, Tang Q, Yang L, Li
L, Wu W and Hann SS: β-elemene inhibited expression of DNA
methyltransferase 1 through activation of ERK1/2 and AMPKa
signalling pathways in human lung cancer cells: The role of Sp1. J
Cell Mol Med. 19:630–641. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guo HQ, Zhang GN, Wang YJ, Zhang YK,
Sodani K, Talele TT, Ashby CR Jr and Chen ZS: β-elemene, a compound
derived from Rhizoma zedoariae, reverses multidrug resistance
mediated by the ABCB1 transporter. Oncol Rep. 31:858–866. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dong Y, Li L, Wang L, Zhou T, Liu JW and
Gao YJ: Preliminary study of the effects of β-elemene on MCF-7/ADM
breast cancer stem cells. Genet Mol Res. 14:2347–2355. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li QQ, Lee RX, Liang H, Wang G, Li JM,
Zhong Y and Reed E: β-elemene enhances susceptibility to cisplatin
in resistant ovarian carcinoma cells via downregulation of ERCC-1
and XIAP and inactivation of JNK. Int J Oncol. 43:721–728. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang J, Zhang HD, Yao YF, Zhong SL, Zhao
JH and Tang JH: β-elemene reverses chemoresistance of breast cancer
cells by reducing resistance transmission via exosomes. Cell
Physiol Biochem. 36:2274–2286. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gottesman MM: How cancer cells evade
chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation
Award Lecture. Cancer Res. 53:747–754. 1993.PubMed/NCBI
|
|
29
|
Gillet JP and Gottesman MM: Mechanisms of
multidrug resistance in cancer. Methods Mol Biol. 596:47–76. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jin MS, Oldham ML, Zhang Q and Chen J:
Crystal structure of the multidrug transporter P- glycoprotein from
Caenorhabditis elegans. Nature. 490:566–569. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shen F, Chu S, Bence AK, Bailey B, Xue X,
Erickson PA, Montrose MH, Beck WT and Erickson LC: Quantitation of
doxorubicin uptake, efflux, and modulation of multidrug resistance
(MDR) in MDR human cancer cells. J Pharmacol Exp Ther. 324:95–102.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Aller SG, Yu J, Ward A, Weng Y,
Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL
and Chang G: Structure of P-glycoprotein reveals a molecular basis
for poly-specific drug binding. Science. 323:1718–1722. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nakamura T, Oka M, Aizawa K, Soda H,
Fukuda M, Terashi K, Ikeda K, Mizuta Y, Noguchi Y, Kimura Y, et al:
Direct interaction between a quinoline derivative, MS-209, and
multidrug resistance protein (MRP) in human gastric cancer cells.
Biochem Biophys Res Commun. 255:618–624. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jovelet C, Bénard J, Forestier F,
Farinotti R, Bidart JM and Gil S: Inhibition of P-glycoprotein
functionality by vandetanib may reverse cancer cell resistance to
doxo-rubicin. Eur J Pharm Sci. 46:484–491. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Angelini A, Conti P, Ciofani G, Cuccurullo
F and Di Ilio C: Modulation of multidrug resistance p-glycoprotein
activity by antiemetic compounds in human doxorubicin-resistant
sarcoma cells (MES-SA/Dx-5): Implications on cancer therapy. J Biol
Regul Homeost Agents. 27:1029–1037. 2013.PubMed/NCBI
|
